Q Therapeutics

Focus: Q Therapeutics is a 5,000+ employee public biotechnology company founded in 2001, headquartered in Salt Lake City, with a stated focus on CNS therapies and neurology.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

5000+

Open Jobs

About Q Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Q Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

Huntington's Disease

N/A

Restylane and Restylane-L

Nasolabial Folds

N/A

Clinical Trials (1)

Help build intelligence for Q Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established 23-year-old public biotech with 5,000+ employees provides organizational stability and career infrastructure larger than typical venture-stage firms
Pipeline includes cell therapy programs (Q-Cells) in high-unmet-need indications like transverse myelitis and ALS, offering cutting-edge modality exposure
Geographic advantage: Salt Lake City location offers lower cost of living than coastal biotech hubs while maintaining public company resources

Watch Out For

Pipeline data is highly fragmented and incoherent—listing malaria, cosmetic derma, umbilical hernia, and other unrelated programs suggests possible data quality issues or massive portfolio sprawl that signals lack of strategic focus
Zero active job openings despite 5,000+ headcount and public status suggests frozen or very limited hiring; company profile lacks recent news, financials, and hiring department breakdowns, indicating either dormancy or data unavailability

Generated by Claude from Q Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT00797459Safety & Tolerability Study That Compares Restylane to Restylane With Lidocaine While Correcting Wrinkles in the Nasolabial Folds

N/A

Androferti

Male Infertility

N/A

Clinical Trials (1)

NCT03466229Impact of Antioxidant Treatment on DNA Fragmentation Index

N/A

Deflux

Umbilical Hernia

N/A

Clinical Trials (1)

NCT00706329Minimally Invasive Closure of Umbilical Hernias

N/A

Brown seaweed

Type II Diabetes

N/A

Clinical Trials (1)

NCT04715776Supplementation of Brown Seaweed on Insulin Resistance of NAFLD Patients With Pre- or Type 2-Diabetes

N/A

Oligo Fucoidan

NSCLC Stage IV

N/A

Clinical Trials (1)

NCT03130829To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC

N/A

Traditional Pilates group

Hypertension

N/A

Clinical Trials (1)

NCT03791307Effects of Training Based on the Pilates Method on the Blood Pressure of Hypertensive Women

N/A

HRQoL surveys

Chronic Obstructive Pulmonary Disease

N/A

Clinical Trials (1)

NCT02406534A Prospective, Observational Study of COPD Patients in U.S. Hospitals

N/A

Oligo Fucoidan

Advanced Hepatocellular Carcinoma

N/A

Clinical Trials (1)

NCT04066660Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

N/A

Perlane and Perlane-L

Nasolabial Folds

N/A

Clinical Trials (1)

NCT00823069Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose

N/A

Xeltis Vascular Patch, Model COR-VP-001

Heart Defects, Congenital

N/A

L-dopa/Carbidopa

Depressive Disorder, Major

N/A

Clinical Trials (1)

NCT05909267Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation

N/A

Use of a PDA to assist shared decision making

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT02110979Validation of a Patient Decision Aid for Type 2 Diabetes

N/A

KAND145

Ovarian Cancer

PHASE_1

MMV390048 40 mg

Malaria

PHASE_1

Clinical Trials (1)

NCT02783820Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Phase 1

Administration of the malaria inoculum

Malaria

PHASE_1

Clinical Trials (1)

NCT02431637Experimental Falciparum Transmission to Anopheles

Phase 1

480 mg Piperaquine phosphate

Malaria

PHASE_1

Clinical Trials (1)

NCT03542149Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP

Phase 1

Placebo

Uterine Leiomyoma

PHASE_1

Clinical Trials (1)

NCT06959966Effects of Oligo-fucoidan on Leiomyoma Patients

Phase 1

SJ733 Induced Blood Stage Malaria Challenge Study

Plasmodium Falciparum Malaria

PHASE_1

Clinical Trials (1)

NCT02867059SJ733 Induced Blood Stage Malaria Challenge Study

Phase 1

MMV390048 20mg

Malaria, Falciparum

PHASE_1

Clinical Trials (1)

NCT02281344MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

Phase 1

Budesonide Inhalation Suspension

Asthma

PHASE_1

Q-Cells

Amyotrophic Lateral Sclerosis

PHASE_1_2

Clinical Trials (1)

NCT02478450Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)

Phase 1/2

Q-Cells

Transverse Myelitis

PHASE_1_2

Clinical Trials (1)

NCT03887273Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis

Phase 1/2

Blood stage parasite

Healthy

PHASE_1_2

Clinical Trials (1)

NCT01055002A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers

Phase 1/2

DSM265

Malaria

PHASE_1_2

Clinical Trials (1)

NCT02573857A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection

Phase 1/2

OZ439

Malaria

PHASE_1_2

Clinical Trials (1)

NCT02431650Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent

Phase 1/2

MMV390048 40mg

Malaria

PHASE_1_2

Clinical Trials (1)

NCT02783833MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B

Phase 1/2

DSM265

Malaria

PHASE_1_2

Clinical Trials (1)

NCT02389348A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265

Phase 1/2

melphalan

Multiple Myeloma and Plasma Cell Neoplasm

PHASE_2

Clinical Trials (1)

NCT00637767High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

Phase 2

Fucoidan

Squamous Cell Carcinomas of the Head and Neck

PHASE_2

Clinical Trials (1)

NCT04597476A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck

Phase 2

Lumentin® 44 Powder for oral foam

Healthy

PHASE_2

Clinical Trials (1)

NCT05781490A Healthy Volunteer Trial Investigating MR-enterography Image Quality of Lumentin® 44

Phase 2

Probiotic L008-1

Smoking Cessation

PHASE_2

Study group - quadrivalent recombinant hemagglutinin influenza vaccine

Influenza, Human

PHASE_3

Clinical Trials (1)

NCT03460743Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2001

Portfolio: 28 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline